Xanthohumol-mediated suppression of Notch1 signaling is associated with antitumor activity in human pancreatic cancer cells

Selvi Kunnimalaiyaan, Jose Trevino, Susan Tsai, T. Clark Gamblin, Muthusamy Kunnimalaiyaan

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer remains a lethal disease with limited treatment options. At the time of diagnosis, approximately 80% of these patients present with unresectable tumors caused by either locally advanced lesions or progressive metastatic growth. Therefore, development of novel treatment strategies and new therapeutics is needed. Xanthohumol (XN) has emerged as a potential compound that inhibits various types of cancer, but the molecular mechanism underlying the effects of XN remains unclear. In the present study, we have assessed the efficacy of XN on pancreatic cancer cell lines (AsPC-1, PANC-1, L3.6pl, MiaPaCa-2, 512, and 651) against cell growth in real time and using colony-forming assays. Treatment with XN resulted in reduction in cellular proliferation in a dose- and time-dependent manner. The growth suppression effect of XN in pancreatic cancer cell lines is due to increased apoptosis via the inhibition of the Notch1 signaling pathway, as evidenced by reduction in Notch1, HES-1, and survivin both at mRNA as well as protein levels. Notch1 promoter reporter analysis after XN treatment indicated that XN downregulates Notch promoter activity. Importantly, overexpression of active Notch1 in XN-treated pancreatic cancer cells resulted in negation of growth suppression. Taken together, these findings demonstrate, for the first time, that the growth suppressive effect of XN in pancreatic cancer cells is mainly mediated by Notch1 reduction.

Original languageEnglish (US)
Pages (from-to)1395-1403
Number of pages9
JournalMolecular Cancer Therapeutics
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Human Activities
Growth
Therapeutics
xanthohumol
Cell Line
Neoplasms
Down-Regulation
Cell Proliferation
Apoptosis
Messenger RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Xanthohumol-mediated suppression of Notch1 signaling is associated with antitumor activity in human pancreatic cancer cells. / Kunnimalaiyaan, Selvi; Trevino, Jose; Tsai, Susan; Gamblin, T. Clark; Kunnimalaiyaan, Muthusamy.

In: Molecular Cancer Therapeutics, Vol. 14, No. 6, 01.06.2015, p. 1395-1403.

Research output: Contribution to journalArticle

Kunnimalaiyaan, Selvi ; Trevino, Jose ; Tsai, Susan ; Gamblin, T. Clark ; Kunnimalaiyaan, Muthusamy. / Xanthohumol-mediated suppression of Notch1 signaling is associated with antitumor activity in human pancreatic cancer cells. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 6. pp. 1395-1403.
@article{f644f19ddf324d2f882734a11ddb93c7,
title = "Xanthohumol-mediated suppression of Notch1 signaling is associated with antitumor activity in human pancreatic cancer cells",
abstract = "Pancreatic cancer remains a lethal disease with limited treatment options. At the time of diagnosis, approximately 80{\%} of these patients present with unresectable tumors caused by either locally advanced lesions or progressive metastatic growth. Therefore, development of novel treatment strategies and new therapeutics is needed. Xanthohumol (XN) has emerged as a potential compound that inhibits various types of cancer, but the molecular mechanism underlying the effects of XN remains unclear. In the present study, we have assessed the efficacy of XN on pancreatic cancer cell lines (AsPC-1, PANC-1, L3.6pl, MiaPaCa-2, 512, and 651) against cell growth in real time and using colony-forming assays. Treatment with XN resulted in reduction in cellular proliferation in a dose- and time-dependent manner. The growth suppression effect of XN in pancreatic cancer cell lines is due to increased apoptosis via the inhibition of the Notch1 signaling pathway, as evidenced by reduction in Notch1, HES-1, and survivin both at mRNA as well as protein levels. Notch1 promoter reporter analysis after XN treatment indicated that XN downregulates Notch promoter activity. Importantly, overexpression of active Notch1 in XN-treated pancreatic cancer cells resulted in negation of growth suppression. Taken together, these findings demonstrate, for the first time, that the growth suppressive effect of XN in pancreatic cancer cells is mainly mediated by Notch1 reduction.",
author = "Selvi Kunnimalaiyaan and Jose Trevino and Susan Tsai and Gamblin, {T. Clark} and Muthusamy Kunnimalaiyaan",
year = "2015",
month = "6",
day = "1",
doi = "10.1158/1535-7163.MCT-14-0915",
language = "English (US)",
volume = "14",
pages = "1395--1403",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Xanthohumol-mediated suppression of Notch1 signaling is associated with antitumor activity in human pancreatic cancer cells

AU - Kunnimalaiyaan, Selvi

AU - Trevino, Jose

AU - Tsai, Susan

AU - Gamblin, T. Clark

AU - Kunnimalaiyaan, Muthusamy

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Pancreatic cancer remains a lethal disease with limited treatment options. At the time of diagnosis, approximately 80% of these patients present with unresectable tumors caused by either locally advanced lesions or progressive metastatic growth. Therefore, development of novel treatment strategies and new therapeutics is needed. Xanthohumol (XN) has emerged as a potential compound that inhibits various types of cancer, but the molecular mechanism underlying the effects of XN remains unclear. In the present study, we have assessed the efficacy of XN on pancreatic cancer cell lines (AsPC-1, PANC-1, L3.6pl, MiaPaCa-2, 512, and 651) against cell growth in real time and using colony-forming assays. Treatment with XN resulted in reduction in cellular proliferation in a dose- and time-dependent manner. The growth suppression effect of XN in pancreatic cancer cell lines is due to increased apoptosis via the inhibition of the Notch1 signaling pathway, as evidenced by reduction in Notch1, HES-1, and survivin both at mRNA as well as protein levels. Notch1 promoter reporter analysis after XN treatment indicated that XN downregulates Notch promoter activity. Importantly, overexpression of active Notch1 in XN-treated pancreatic cancer cells resulted in negation of growth suppression. Taken together, these findings demonstrate, for the first time, that the growth suppressive effect of XN in pancreatic cancer cells is mainly mediated by Notch1 reduction.

AB - Pancreatic cancer remains a lethal disease with limited treatment options. At the time of diagnosis, approximately 80% of these patients present with unresectable tumors caused by either locally advanced lesions or progressive metastatic growth. Therefore, development of novel treatment strategies and new therapeutics is needed. Xanthohumol (XN) has emerged as a potential compound that inhibits various types of cancer, but the molecular mechanism underlying the effects of XN remains unclear. In the present study, we have assessed the efficacy of XN on pancreatic cancer cell lines (AsPC-1, PANC-1, L3.6pl, MiaPaCa-2, 512, and 651) against cell growth in real time and using colony-forming assays. Treatment with XN resulted in reduction in cellular proliferation in a dose- and time-dependent manner. The growth suppression effect of XN in pancreatic cancer cell lines is due to increased apoptosis via the inhibition of the Notch1 signaling pathway, as evidenced by reduction in Notch1, HES-1, and survivin both at mRNA as well as protein levels. Notch1 promoter reporter analysis after XN treatment indicated that XN downregulates Notch promoter activity. Importantly, overexpression of active Notch1 in XN-treated pancreatic cancer cells resulted in negation of growth suppression. Taken together, these findings demonstrate, for the first time, that the growth suppressive effect of XN in pancreatic cancer cells is mainly mediated by Notch1 reduction.

UR - http://www.scopus.com/inward/record.url?scp=84939464044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939464044&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-14-0915

DO - 10.1158/1535-7163.MCT-14-0915

M3 - Article

AN - SCOPUS:84939464044

VL - 14

SP - 1395

EP - 1403

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 6

ER -